How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

5,802 results for

Amyotrophic Lateral Sclerosis

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Amyotrophic lateral sclerosis

Amyotrophic lateral sclerosis Amyotrophic lateral sclerosis - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Amyotrophic lateral sclerosis Last reviewed: February 2019 Last updated: February 2019 Summary Progressive disease characterised by degeneration of the motor neurons with cortical, brainstem, and ventral cord locations. Usually presents as a combination of upper motor neuron and lower motor neuron symptoms (...) care is to provide supportive and palliative intervention, aiming to improve the quality of life for patients. Riluzole is used for modifying the disease course and should be offered to patients at the time of diagnosis. Continued discussions regarding advance directives, as well as methods of respiratory and nutritional support are critical; palliative care options should also be presented and discussed prior to the need for their initiation. Definition Amyotrophic lateral sclerosis (ALS

2019 BMJ Best Practice

2. Edaravone (Radicava) - for the treatment of amyotrophic lateral sclerosis

Edaravone (Radicava) - for the treatment of amyotrophic lateral sclerosis Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Expand all Summary Basis of Decision (SBD) for Contact: Summary Basis of Decision (SBD) documents provide information related to the original authorization of a product. The for is located below. Recent Activity for SBDs written for approved

2019 Health Canada - Drug and Health Product Register

3. Treatment of fatigue in amyotrophic lateral sclerosis/motor neuron disease. Full Text available with Trip Pro

Treatment of fatigue in amyotrophic lateral sclerosis/motor neuron disease. Amyotrophic lateral sclerosis (ALS), also known as motor neuron disease (MND), is terminal, progressive neurological condition for which there are no curative treatments. Among people with ALS/MND, fatigue is a common and debilitating symptom, which is characterised by reversible motor weakness and whole-body tiredness that is only partially relieved by rest. The effectiveness of pharmacological or non-pharmacological

2018 Cochrane

4. Radicava - edaravone - amyotrophic lateral sclerosis

Radicava - edaravone - amyotrophic lateral sclerosis edaravone | CADTH.ca Find the information you need edaravone edaravone Last Updated: April 24, 2019 Result type: Reports Project Number: SR0573-000 Product Line: Generic Name: edaravone Brand Name: Radicava Manufacturer: Mitsubishi Tanabe Pharma Corporation Indications: amyotrophic lateral sclerosis Manufacturer Requested Reimbursement Criteria 1 : For the treatment of amyotrophic lateral sclerosis (ALS). Submission Type: New Project Status

2018 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

5. Masitinib mesylate (Alsitek) - Amyotrophic Lateral Sclerosis

Masitinib mesylate (Alsitek) - Amyotrophic Lateral Sclerosis 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact © European Medicines Agency, 2018. Reproduction is authorised provided the source is acknowledged. 18 April 2018 EMA/406203/2018 Committee for Medicinal Products for Human Use (CHMP) Assessment report Alsitek (...) sclerosis. The applicant applied for the following indication: Masitinib is indicated for the treatment of adult patients with probable or definitive amyotrophic lateral sclerosis (ALS). Masitinib is administered as dual oral therapy in combination with riluzole. The legal basis for this application refers to: Article 8.3 of Directive 2001/83/EC - complete and independent application The application submitted is composed of administrative information, complete quality data, non- clinical and clinical

2018 European Medicines Agency - EPARs

7. Home mechanical ventilation for patients with Amyotrophic Lateral Sclerosis: A CTS Clinical Practice Guideline

Home mechanical ventilation for patients with Amyotrophic Lateral Sclerosis: A CTS Clinical Practice Guideline CTS GUIDELINES AND POSITION PAPERS Home mechanical ventilation for patients with Amyotrophic Lateral Sclerosis: A Canadian Thoracic Society clinical practice guideline Karen P. Rimmer a , Marta Kaminska b , Mika Nonoyama c , Eleni Giannouli d , Franc ¸ois Maltais e , Debra L. Morrison f , Colleen O’Connell g , Basil J. Petrof h , and Douglas A. McKim i a University of Calgary, Calgary (...) for Rehabilitation, Fredericton, New Brunswick, Canada; h Meakins-Christie Laboratories, McGill University Health Centre, Montr eal, Qu ebec, Canada; i Division of Respirology, University of Ottawa and The Ottawa Hospital Research Institute, CANVent Respiratory Services, Ottawa, Ontario, Canada ABSTRACT Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disorder involving both upper and lower motor neurons that results in progressive weakness of skeletal muscles. Regardless of site of first onset, death

2019 Canadian Thoracic Society

8. Amyotrophic lateral sclerosis

Amyotrophic lateral sclerosis Amyotrophic lateral sclerosis - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Amyotrophic lateral sclerosis Last reviewed: February 2019 Last updated: February 2019 Summary Progressive disease characterised by degeneration of the motor neurons with cortical, brainstem, and ventral cord locations. Usually presents as a combination of upper motor neuron and lower motor neuron symptoms (...) care is to provide supportive and palliative intervention, aiming to improve the quality of life for patients. Riluzole is used for modifying the disease course and should be offered to patients at the time of diagnosis. Continued discussions regarding advance directives, as well as methods of respiratory and nutritional support are critical; palliative care options should also be presented and discussed prior to the need for their initiation. Definition Amyotrophic lateral sclerosis (ALS

2017 BMJ Best Practice

9. Mechanical ventilation for amyotrophic lateral sclerosis/motor neuron disease. Full Text available with Trip Pro

Mechanical ventilation for amyotrophic lateral sclerosis/motor neuron disease. Amyotrophic lateral sclerosis (ALS), also known as motor neuron disease, is a fatal neurodegenerative disease. Neuromuscular respiratory failure is the most common cause of death, which usually occurs within two to five years of the disease onset. Supporting respiratory function with mechanical ventilation may improve survival and quality of life. This is the second update of a review first published in 2009

2017 Cochrane

10. Symptomatic treatments for amyotrophic lateral sclerosis/motor neuron disease. Full Text available with Trip Pro

Symptomatic treatments for amyotrophic lateral sclerosis/motor neuron disease. Motor neuron disease (MND), which is also known as amyotrophic lateral sclerosis (ALS), causes a wide range of symptoms but the evidence base for the effectiveness of the symptomatic treatment therapies is limited.To summarise the evidence from Cochrane Systematic Reviews of all symptomatic treatments for MND.We searched the Cochrane Database of Systematic Reviews (CDSR) on 15 November 2016 for systematic reviews

2017 Cochrane

11. Edaravone (Radicava) - To treat patients with amyotrophic lateral sclerosis (ALS)

Edaravone (Radicava) - To treat patients with amyotrophic lateral sclerosis (ALS) Radicava (edaravone) Injection U.S. Department of Health and Human Services Search FDA Submit search Radicava (edaravone) Injection Radicava Company: Mitsubishi Tanabe Pharma Development America, Inc. Application No.: 209176 Approval Date: 05/05/2017 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF

2017 FDA - Drug Approval Package

12. Cell-based therapies for amyotrophic lateral sclerosis/motor neuron disease. Full Text available with Trip Pro

Cell-based therapies for amyotrophic lateral sclerosis/motor neuron disease. Amyotrophic lateral sclerosis (ALS), which is also known as motor neuron disease (MND) is a fatal disease associated with rapidly progressive disability, for which no definitive treatment as yet exists. Current treatment regimens largely focus on relieving symptoms to improve the quality of life of those affected. Based on data from preclinical studies, cell-based therapy is a promising treatment for ALS/MND.To assess

2016 Cochrane

13. Bulbar impairment score and survival of stable amyotrophic lateral sclerosis patients after noninvasive ventilation initiation Full Text available with Trip Pro

Bulbar impairment score and survival of stable amyotrophic lateral sclerosis patients after noninvasive ventilation initiation There is general agreement that noninvasive ventilation (NIV) prolongs survival in amyotrophic lateral sclerosis (ALS) and that the main cause of NIV failure is the severity of bulbar dysfunction. However, there is no evidence that bulbar impairment is a contraindication for NIV. The aim of this study was to determine the effect of bulbar impairment on survival in ALS

2018 ERJ open research

14. Exploring the Use of Educational Material About Shoulder Dysfunction: A Quality Improvement Project in People With Amyotrophic Lateral Sclerosis Full Text available with Trip Pro

Exploring the Use of Educational Material About Shoulder Dysfunction: A Quality Improvement Project in People With Amyotrophic Lateral Sclerosis Shoulder pain is a common secondary complication of amyotrophic lateral sclerosis (ALS) that can contribute to functional decline and decreased participation in daily activities. The purpose of this study was to assess the effectiveness of an educational brochure aimed at improving knowledge regarding shoulder pain and dysfunction in people with ALS

2018 American journal of physical medicine & rehabilitation

15. RNA-Targeted Therapies and Amyotrophic Lateral Sclerosis Full Text available with Trip Pro

RNA-Targeted Therapies and Amyotrophic Lateral Sclerosis Amyotrophic lateral sclerosis (ALS) is a fatal motor disease in adults. Its pathophysiology remains mysterious, but tremendous advances have been made with the discovery of the most frequent mutations of its more common familial form linked to the C9ORF72 gene. Although most cases are still considered sporadic, these genetic mutations have revealed the role of RNA production, processing and transport in ALS, and may be important players

2018 Biomedicines

16. Cortico-efferent tract involvement in primary lateral sclerosis and amyotrophic lateral sclerosis: A two-centre tract of interest-based DTI analysis Full Text available with Trip Pro

Cortico-efferent tract involvement in primary lateral sclerosis and amyotrophic lateral sclerosis: A two-centre tract of interest-based DTI analysis After the demonstration of a corticoefferent propagation pattern in amyotrophic lateral sclerosis (ALS) by neuropathological studies, this concept has been used for in vivo staging of individual patients by diffusion tensor imaging (DTI) techniques, both in `classical` ALS and in restricted phenotypes such as primary lateral sclerosis (PLS

2018 NeuroImage : Clinical

17. Identical patterns of cortico-efferent tract involvement in primary lateral sclerosis and amyotrophic lateral sclerosis: A tract of interest-based MRI study Full Text available with Trip Pro

Identical patterns of cortico-efferent tract involvement in primary lateral sclerosis and amyotrophic lateral sclerosis: A tract of interest-based MRI study There is an ongoing debate whether primary lateral sclerosis (PLS) should be regarded as an independent disease entity separate from amyotrophic lateral sclerosis (ALS) or as a slowly progressive variant of ALS.The study was designed to investigate specific white matter alterations in diffusion tensor imaging (DTI) data from PLS patients

2018 NeuroImage : Clinical

18. In silico analysis of PFN1 related to amyotrophic lateral sclerosis. Full Text available with Trip Pro

In silico analysis of PFN1 related to amyotrophic lateral sclerosis. Profilin 1 (PFN1) protein plays key roles in neuronal growth and differentiation, membrane trafficking, and regulation of the actin cytoskeleton. Four natural variants of PFN1 were described as related to ALS, the most common adult-onset motor neuron disorder. However, the pathological mechanism of PFN1 in ALS is not yet completely understood. The goal of this work is to thoroughly analyze the effects of the ALS-related

2019 PLoS ONE

19. Repeated Intrathecal Mesenchymal Stem Cells for Amyotrophic Lateral Sclerosis Full Text available with Trip Pro

Repeated Intrathecal Mesenchymal Stem Cells for Amyotrophic Lateral Sclerosis To assess the safety and efficacy of 2 repeated intrathecal injections of autologous bone marrow-derived mesenchymal stem cells (BM-MSCs) in amyotrophic lateral sclerosis (ALS).In a phase 2 randomized controlled trial (NCT01363401), 64 participants with ALS were randomly assigned treatments (1:1) of riluzole alone (control group, n = 31) or combined with 2 BM-MSC injections (MSC group, n = 33). Safety was assessed (...) based on the occurrence of adverse events. The primary efficacy outcome was changes in Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) score from baseline to 4 and 6 months postinjection. Post hoc analysis includes investigation of cerebrospinal fluid biomarkers and long-term survival analysis.Safety rating showed no groupwise difference with absence of serious treatment-related adverse events. Mean changes in ALSFRS-R scores from baseline to 4 and 6 months postinjection

2018 EvidenceUpdates

20. Safety and efficacy of rasagiline as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomised, double-blind, parallel-group, placebo-controlled, phase 2 trial (Abstract)

Safety and efficacy of rasagiline as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomised, double-blind, parallel-group, placebo-controlled, phase 2 trial Rasagiline, a monoamine oxidase B inhibitor with neuroprotective potential in Parkinson's disease, has shown a disease-modifying effect in the SOD1-Gly93Ala low-expressing mouse model of amyotrophic lateral sclerosis, both alone and in combination with riluzole. We sought to test whether or not rasagiline (...) 1 mg/day can prolong survival in patients with amyotrophic lateral sclerosis also receiving riluzole.Patients with possible, probable, or definite amyotrophic lateral sclerosis were enrolled to our randomised, placebo-controlled, parallel-group, double-blind, phase 2 trial from 15 German network for motor neuron diseases (MND-NET) centres (university hospitals or clinics). Eligible patients were aged at least 18 years, had onset of progressive weakness within the 36 months before the study, had

2018 EvidenceUpdates

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>